How tirzepatide works: the dual GIP/GLP-1 science explained
Two gut hormones, one engineered molecule. The dual mechanism behind tirzepatide's results — and why it outperformed semaglutide head-to-head.
Two incretins, not one
After you eat, your gut releases hormones called incretins that coordinate the body's response to food. The two most important are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Semaglutide targets only the GLP-1 receptor. Tirzepatide is the first approved medication to activate both the GIP and GLP-1 receptors in a single molecule — which is why it is described as a dual agonist or "twincretin." Both hormones influence insulin secretion, appetite, and how the body handles fat and glucose, but through partly different tissues and pathways.
What tirzepatide does at the receptors
Tirzepatide binds and activates both receptors, amplifying the appetite-suppressing and gastric-slowing effects patients notice most: meals feel satisfying sooner, hunger falls, and total caloric intake drops. Over months this produces the weight loss quantified in SURMOUNT-1 (up to ~20.9%). The GLP-1 arm drives much of the appetite and glucose effect; the GIP arm appears to contribute additional weight loss and may buffer some of the nausea that pure GLP-1 activation can cause, though this is still an area of active research.
Why dual action appears to beat single action
The clearest evidence that two receptors matter is the head-to-head SURMOUNT-5 result, where tirzepatide produced about 20.2% mean weight loss versus 13.7% for semaglutide over 72 weeks. Mechanistically, the leading interpretation is that GIP receptor activation adds to the appetite and metabolic effects of GLP-1 rather than duplicating them — engaging additional pathways in the brain and adipose tissue. This is not merely academic: it is the reason tirzepatide occupies the top of the efficacy frontier among approved weight-management drugs, and why so many patients and prescribers weigh it against semaglutide despite its higher typical cost.
Why it's a once-weekly injection
Natural incretins last only minutes. Tirzepatide is engineered with a fatty-acid chain that binds albumin in the blood, extending its half-life to about five days — long enough for stable once-weekly dosing. That design underpins the slow titration schedule, which governs both efficacy and tolerability, and on dose-tiered plans, your monthly bill. Nothing about tirzepatide's behavior is arbitrary once you see the biology underneath it.
Mounjaro vs Zepbound: same molecule, two brands
Tirzepatide is sold under two brand names, which confuses many shoppers. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and obstructive sleep apnea in adults with obesity. They contain the identical molecule at the same dose strengths; the difference is the approved indication and, sometimes, insurance coverage rules. In the compounded market, "tirzepatide" refers to the same active ingredient regardless of which brand a program compares itself to, but compounded tirzepatide is not FDA-approved and is not either brand. Understanding that one molecule sits behind two brand names — and behind every compounded listing — is the key to reading tirzepatide pricing and marketing accurately.
What the mechanism means for your treatment
Once you understand the dual mechanism, the practical rules of tirzepatide stop feeling arbitrary and start following from the biology. The once-weekly schedule follows from the roughly five-day half-life. The slow titration follows from the fact that the gut effects driving nausea are strongest when the dose changes. The weight regain after stopping follows from the simple fact that the appetite-suppressing signal disappears once the drug clears, so the biological drive to eat returns toward its prior set point. The dose-dependent efficacy — more loss at 15 mg than 5 mg — follows from greater receptor engagement. For a patient, this coherence is useful: the guidance a good provider gives is not a set of disconnected rules but a single dual mechanism expressed in different ways, and working with it rather than against it, by titrating patiently and planning for the long term, is the throughline of successful treatment.
Frequently asked questions
How does tirzepatide work?
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates two gut-hormone receptors at once, slowing gastric emptying, reducing appetite, and improving glucose handling — together reducing food intake and producing weight loss.
Why is tirzepatide more effective than semaglutide?
The leading explanation is its dual mechanism: adding GIP receptor activation to GLP-1 appears to amplify weight loss and may improve tolerability. In SURMOUNT-5, tirzepatide produced greater average loss than semaglutide (20.2% vs 13.7%).
Is tirzepatide the same as Mounjaro and Zepbound?
Tirzepatide is the active ingredient in both Mounjaro (type 2 diabetes) and Zepbound (weight management and sleep apnea). Compounded tirzepatide contains the same molecule but is not FDA-approved.
Why is tirzepatide injected only once a week?
It is engineered with a fatty-acid chain that binds albumin, extending its half-life to about five days, which allows stable once-weekly dosing.
References
- Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022.
- Aronne LJ, et al. SURMOUNT-5 head-to-head. N Engl J Med. 2025.
- Eli Lilly. Mounjaro and Zepbound Prescribing Information — clinical pharmacology.
- WeightLoss GLP-1 science journal, July 2026.
Clinical figures from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026 and subject to change. Educational, not medical or financial advice.